DK0900380T3 - Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper - Google Patents

Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper

Info

Publication number
DK0900380T3
DK0900380T3 DK97919749T DK97919749T DK0900380T3 DK 0900380 T3 DK0900380 T3 DK 0900380T3 DK 97919749 T DK97919749 T DK 97919749T DK 97919749 T DK97919749 T DK 97919749T DK 0900380 T3 DK0900380 T3 DK 0900380T3
Authority
DK
Denmark
Prior art keywords
epitopes
vaccines
cell
present
selection
Prior art date
Application number
DK97919749T
Other languages
English (en)
Inventor
Der Burg Sjoerd Henricus Van
Wybe Martin Kast
Reinaldus Everardus Maria Toes
Rienk Offringa
Cornelius Johannes Mari Melief
Original Assignee
Seed Capital Investments
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seed Capital Investments, Univ Leiden filed Critical Seed Capital Investments
Application granted granted Critical
Publication of DK0900380T3 publication Critical patent/DK0900380T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
DK97919749T 1996-04-26 1997-04-28 Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper DK0900380T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96203670 1996-12-23
PCT/NL1997/000229 WO1997041440A1 (en) 1996-04-26 1997-04-28 Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes

Publications (1)

Publication Number Publication Date
DK0900380T3 true DK0900380T3 (da) 2003-11-03

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919749T DK0900380T3 (da) 1996-04-26 1997-04-28 Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper

Country Status (11)

Country Link
US (1) US20070025968A1 (da)
EP (1) EP0900380B1 (da)
JP (1) JP4108126B2 (da)
AT (1) ATE244891T1 (da)
AU (1) AU738649B2 (da)
CA (1) CA2252675A1 (da)
DE (1) DE69723434T2 (da)
DK (1) DK0900380T3 (da)
ES (1) ES2205209T3 (da)
PT (1) PT900380E (da)
WO (1) WO1997041440A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
AU732468B2 (en) * 1997-06-23 2001-04-26 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
CN1762492A (zh) * 1998-05-23 2006-04-26 莱顿大学医学中心 Cd40结合分子和ctl肽在用于治疗肿瘤的药物组合物中的用途
ATE429247T1 (de) * 1998-06-17 2009-05-15 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
US6685944B1 (en) 1998-08-21 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Modified HCV peptide vaccines
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001023577A2 (en) * 1999-09-30 2001-04-05 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DE60043158D1 (de) 1999-11-18 2009-11-26 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU780064B2 (en) * 1999-12-28 2005-02-24 Epimmune, Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
CA2405363A1 (en) * 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Epitope synchronization in antigen presenting cells
AU2001278117A1 (en) 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
CN1469883A (zh) * 2000-08-21 2004-01-21 ��Ƥ���ռ���(����˹�ж�)���޹�˾ 肽选择方法
AU2000275748A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
MXPA03010527A (es) * 2001-05-18 2004-07-01 Powderject Vaccines Inc Composicion de vacuna.
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (en) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
DK2714071T3 (da) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP3417874A1 (en) 2012-11-28 2018-12-26 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
JPWO2019054409A1 (ja) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Ｈｌａタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット
AU2018437560A1 (en) * 2018-08-23 2021-02-18 Grid Powr (Australia) Pty Ltd Process and device for improving of synthesis and/or flue gas velocity field for refuse derived fuel applications
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
AU7958994A (en) * 1993-10-05 1995-05-01 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
CA2252675A1 (en) 1997-11-06
AU738649B2 (en) 2001-09-20
EP0900380B1 (en) 2003-07-09
AU2410697A (en) 1997-11-19
JP2000510689A (ja) 2000-08-22
DE69723434T2 (de) 2004-05-19
ES2205209T3 (es) 2004-05-01
DE69723434D1 (de) 2003-08-14
PT900380E (pt) 2003-12-31
JP4108126B2 (ja) 2008-06-25
US20070025968A1 (en) 2007-02-01
WO1997041440A1 (en) 1997-11-06
ATE244891T1 (de) 2003-07-15
EP0900380A1 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
DK0900380T3 (da) Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
Widmann et al. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides
Lachmann et al. Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
HUP0402048A2 (hu) Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására
DK1090039T3 (da) Peptidsammensætning som immunogen til behandling af allergi
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
EP0794797A4 (en) METHODS AND EQUIPMENT FOR IMMUNIZING A HOST BY ADMINISTERING NAKED POLYNUCLEOTIDES ENCODING ANTIGEN PEPTIDES
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
DK1098910T3 (da) Antigenkompleks indeholdende immunstimulerende peptid, CD4 og chemokinreceptordomæne til behandling af HIV og immunsygdomme
HUP9903770A2 (hu) Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
EP0753009B1 (en) Malaria peptides
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
EA200300640A1 (ru) Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью
Delavari et al. Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
Rodrigues-da-Silva et al. Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9
DK0701612T3 (da) Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti
Bittner‐Eddy et al. Identification of gingipain‐specific I‐A b‐restricted CD 4+ T cells following mucosal colonization with P orphyromonas gingivalis in C 57 BL/6 mice
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
WAHLGREN et al. Epitopes of the Plasmodium falciparum clustered‐asparagine‐rich protein (CARP) recognized by human T‐cells and antibodies